Literature DB >> 20471189

MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: quantitative and model-based gadobenate dimeglumine MRP parameters in detection of prostate cancer.

M K Scherr1, M Seitz, U G Müller-Lisse, M Ingrisch, M F Reiser, U L Müller-Lisse.   

Abstract

BACKGROUND: Various MR methods, including MR-spectroscopy (MRS), dynamic, contrast-enhanced MRI (DCE-MRI), and diffusion-weighted imaging (DWI) have been applied to improve test quality of standard MRI of the prostate.
PURPOSE: To determine if quantitative, model-based MR-perfusion (MRP) with gadobenate dimeglumine (Gd-BOPTA) discriminates between prostate cancer, benign tissue, and transitional zone (TZ) tissue.
MATERIAL AND METHODS: 27 patients (age, 65±4 years; PSA 11.0±6.1 ng/ml) with clinical suspicion of prostate cancer underwent standard MRI, 3D MR-spectroscopy (MRS), and MRP with Gd-BOPTA. Based on results of combined MRI/MRS and subsequent guided prostate biopsy alone (17/27), biopsy and radical prostatectomy (9/27), or sufficient negative follow-up (7/27), maps of model-free, deconvolution-based mean transit time (dMTT) were generated for 29 benign regions (bROIs), 14 cancer regions (cROIs), and 18 regions of transitional zone (tzROIs). Applying a 2-compartment exchange model, quantitative perfusion analysis was performed including as parameters: plasma flow (PF), plasma volume (PV), plasma mean transit time (PMTT), extraction flow (EFL), extraction fraction (EFR), interstitial volume (IV) and interstitial mean transit time (IMTT). Two-sided T-tests (significance level p<0.05) discriminated bROIs vs. cROIs and cROIs vs. tzROIs, respectively.
RESULTS: PMTT discriminated best between bROIs (11.8±3.0 s) and cROIs (24.3±9.6 s) (p<0.0001), while PF, PV, PS, EFR, IV, IMTT also differed significantly (p 0.00002-0.0136). Discrimination between cROIs and tzROIs was insignificant for all parameters except PV (14.3±2.5 ml vs. 17.6±2.6 ml, p<0.05).
CONCLUSIONS: Besides MRI, MRS and DWI quantitative, 2-compartment MRP with Gd-BOPTA discriminates between prostate cancer and benign tissue with several parameters. However, distinction of prostate cancer and TZ does not appear to be reliable.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471189     DOI: 10.1016/j.ejrad.2010.04.023

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

1.  UMMPerfusion: an open source software tool towards quantitative MRI perfusion analysis in clinical routine.

Authors:  Frank G Zöllner; Gerald Weisser; Marcel Reich; Sven Kaiser; Stefan O Schoenberg; Steven P Sourbron; Lothar R Schad
Journal:  J Digit Imaging       Date:  2013-04       Impact factor: 4.056

Review 2.  Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer.

Authors:  Michael Ingrisch; Steven Sourbron
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-06       Impact factor: 2.745

Review 3.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

4.  Feasibility study of computed vs measured high b-value (1400 s/mm²) diffusion-weighted MR images of the prostate.

Authors:  Leonardo K Bittencourt; Ulrike I Attenberger; Daniel Lima; Ralph Strecker; Andre de Oliveira; Stefan O Schoenberg; Emerson L Gasparetto; Daniel Hausmann
Journal:  World J Radiol       Date:  2014-06-28

5.  Feasibility study of CT perfusion imaging for prostate carcinoma.

Authors:  Nesat Cullu; Mecit Kantarci; Hayri Ogul; Senol Adanur; Aylin Okur; Erdem Koc; Berhan Pirimoglu; Leyla Karaca; Yesim Kizrak; Ozkan Polat
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

Review 6.  A decade in prostate cancer: from NMR to metabolomics.

Authors:  Elita M DeFeo; Chin-Lee Wu; W Scott McDougal; Leo L Cheng
Journal:  Nat Rev Urol       Date:  2011-05-17       Impact factor: 14.432

Review 7.  Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer.

Authors:  John V Hegde; Robert V Mulkern; Lawrence P Panych; Fiona M Fennessy; Andriy Fedorov; Stephan E Maier; Clare M C Tempany
Journal:  J Magn Reson Imaging       Date:  2013-05       Impact factor: 4.813

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.